The rapid development of molecular targeted therapy brings hope to patients with advanced
non-small-cell lung cancer (NSCLC). However, drug resistance inevitably occurs during …

India is a land of diversity with a motley of cultures, religions, languages, festivals, and ethnic
groups. The country's population as of 2020 is more than 1.38 billion, which accounts for …

Opinion statement Despite advancements in clinical research, both prognosis and treatment
for SCLC patients are still in the nascent stage. SCLC is a fatal disease with high tumor …

BRAF and cMET exon 14 skipping are rare mutations of NSCLC. The treatment sequence in
these cases for the first and second line is not clear. An international registry was created for …

Introduction Pembrolizumab is recommended with a fixed dose of 200 mg 3-weekly. We
performed this study to explore the clinical efficacy and safety of pharmacokinetic (PK) …

Metastasis stands as the primary contributor to mortality associated with tumors.
Chemotherapy and immunotherapy are frequently utilized in the management of metastatic …

Simple Summary Lung cancer is a heterogeneous group of diseases in both morphology
and molecular subtypes. There are two main histological categories of lung cancer: small …

Simple Summary The aim of this innovative review is to highlight the treatment strategies
beyond immune-checkpoint inhibitor (ICI)-based first-line therapy failure according to …

Introduction Programmed death-ligand 1 (PD-L1) immunohistochemistry (IHC) is required to
determine the eligibility for pembrolizumab monotherapy in advanced NSCLC worldwide …

Lung cancer has the world's second highest cancer incidence and second highest cancer-
related mortality rate. However, the mechanism underlying non-small cell lung cancer …